(NASDAQ: PASG) Passage Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41%.
Passage Bio's earnings in 2025 is -$56,855,000.On average, 7 Wall Street analysts forecast PASG's earnings for 2025 to be -$44,765,137, with the lowest PASG earnings forecast at -$45,823,648, and the highest PASG earnings forecast at -$43,956,791. On average, 6 Wall Street analysts forecast PASG's earnings for 2026 to be -$19,008,050, with the lowest PASG earnings forecast at -$33,986,132, and the highest PASG earnings forecast at -$9,512,290.
In 2027, PASG is forecast to generate -$14,606,490 in earnings, with the lowest earnings forecast at -$23,612,729 and the highest earnings forecast at -$4,272,186.